These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
743 related articles for article (PubMed ID: 19128681)
1. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre. Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681 [TBL] [Abstract][Full Text] [Related]
2. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin? Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617 [TBL] [Abstract][Full Text] [Related]
3. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses. Dennis K; Hay JH; Wilson DC Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464 [TBL] [Abstract][Full Text] [Related]
4. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer. Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586 [TBL] [Abstract][Full Text] [Related]
5. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Trybek T; Kowalska A; Lesiak J; Młynarczyk J Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108 [TBL] [Abstract][Full Text] [Related]
6. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493 [TBL] [Abstract][Full Text] [Related]
7. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Ozkan E; Aras G; Kucuk NO Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605 [TBL] [Abstract][Full Text] [Related]
9. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Ong SC; Ng DC; Sundram FX Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358 [TBL] [Abstract][Full Text] [Related]
10. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959 [TBL] [Abstract][Full Text] [Related]
11. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma. Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600 [TBL] [Abstract][Full Text] [Related]
12. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer. Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523 [TBL] [Abstract][Full Text] [Related]
15. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259 [TBL] [Abstract][Full Text] [Related]
16. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699 [TBL] [Abstract][Full Text] [Related]
17. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245 [TBL] [Abstract][Full Text] [Related]
18. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan]. Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773 [TBL] [Abstract][Full Text] [Related]
19. The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels. Ozkan E; Soydal C; Araz M; Aras G; Ibis E Clin Nucl Med; 2012 Aug; 37(8):755-8. PubMed ID: 22785502 [TBL] [Abstract][Full Text] [Related]
20. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]